March 6, 2024
Mitsubishi Tanabe Pharma and Daiichi Sankyo will terminate their marketing alliance for diabetes drugs Tenelia (teneligliptin) and Canaglu (canagliflozin) on September 2 due to the expiration of their agreement. Currently, Tenelia, a DPP-4 inhibitor, is sold by Daiichi Sankyo and...read more